Neuropathic Pain Market and Forecast Analysis to 2024

  • ID: 4533528
  • Report
  • 73 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory system, resulting in symptoms that include burning, stabbing, shooting, or electric shock-like sensations, which substantially differentiate it from nociceptive pain. Neuropathic pain is not a single disease, but a syndrome caused by an array of different diseases and lesions, with common subtypes such as diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathic pain.

Market Snapshot
  • Treatment of neuropathic pain has remained stagnant over recent years due to lack of innovation within the pain market.
  • The burden of neuropathic pain is difficult to estimate, but is likely high across all analyzed countries.
Note: Product cover images may vary from those shown
2 of 3
TREATMENT: NEUROPATHIC PAIN (Published on 13 March 2018)

OVERVIEW

EXECUTIVE SUMMARY

PRIMARY RESEARCH METHODOLOGY

DISEASE DEFINITION AND DIAGNOSIS

PATIENT SEGMENTATION

CURRENT TREATMENT OPTIONS

PRESCRIBING TRENDS

UNMET NEEDS IN NEUROPATHIC PAIN

EPIDEMIOLOGY: NEUROPATHIC PAIN (Published on 16 March 2018)

OVERVIEW

DISEASE BACKGROUND

METHODOLOGY

FORECAST

BIBLIOGRAPHY

List of Figures
Figure 1: Surveyed respondents’ neuropathic pain patient caseload, by pain subtype
Figure 2: Surveyed respondents’ neuropathic pain patient caseload, by pain severity
Figure 3: 2010 EFNS recommendations for neuropathic pain
Figure 4: Neuropathic pain pharmacological treatment rates, by pain subtype
Figure 5: Top five therapies among first-line painful diabetic peripheral neuropathy patients, by country (%)
Figure 6: Top five therapies among second-line and beyond painful diabetic peripheral neuropathy patients, by country (%)
Figure 7: Top five therapies among first-line post-herpetic neuralgia patients, by country (%)
Figure 8: Top five therapies among second-line post-herpetic neuralgia patients, by country (%)
Figure 9: Top five therapies among first-line chemotherapy-induced peripheral neuropathy patients, by country (%)
Figure 10: Top five therapies among second-line chemotherapy-induced peripheral neuropathy patients, by country (%)
Figure 11: Top five therapies among first-line post-herpetic neuralgia patients, by country (%)
Figure 12: Top five therapies among second-line other chronic neuropathic pain patients, by country (%)
Figure 13: Key unmet needs for neuropathic pain
Figure 14: Trends in total prevalent cases of neuropathic pain in the US, Japan, and five major EU markets, by country, 2017-37

List of Tables
Table 1: Primary care physicians and specialists surveyed for the neuropathic pain primary research study, 2017
Table 2: Therapies discussed in the neuropathic pain key opinion leader primary research study, December 2017
Table 3: Common neuropathic pain conditions and their etiology
Table 4: Treatments available for neuropathic pain across the US, Japan, and five major EU markets
Table 5: International Association for the Study of Pain recommendations
Table 6: Treatment strategies for painful diabetic peripheral neuropathy patients, by country (%)
Table 7: Treatment strategies for post-herpetic neuralgia patients, by country (%)
Table 8: Treatment strategies for chemotherapy-induced peripheral neuropathy, by country (%)
Table 9: Treatment strategies for other chronic neuropathic pain patients, by country (%)
Table 10: Compliance rates of neuropathic pain patients across the US, Japan, and five major EU markets, by therapy type and country
Table 11: Relative importance of unmet needs in neuropathic pain treatment in the US, Japan, and five major EU markets, by country
Table 12: Sources used for painful peripheral diabetic neuropathy analysis in the US, Japan, and five major EU markets
Table 13: Segmentation of total neuropathic pain patients by pain type, by country
Table 14: Total prevalent cases of neuropathic pain in the US, Japan, and five major EU markets, by country, 2017-37
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll